e-Therapeutics signs two collaboration deals to enhance AI technology capabilities

This article was originally published here

PBR Staff Writer Published 16 January 2018

UK-based drug developer e-Therapeutics has agreed to collaborate with Intellegens and Biorelate to improve and extend its artificial intelligence (AI) technology capabilities.

Intellegens and Biorelate have AI tools, which can enhance e-Therapeutics’ existing computational network-driven drug discovery (NDD) technology.

Intellegens is a spin-out from the University of Cambridge, which has developed an AI method to train neural networks from incomplete data.

The deal will enable allow e-Therapeutics to use Intellegens’ technology for predication and error correction of large-scale biological and chemical data.

It will help to train neural networks on the sparse data typical of biological and chemical problems. The technology can also be used to develop advanced computationally guided approach to medicinal chemistry.

Based in Manchester, Biorelate uses AI technology to create curated databases by analysing published literature.

The firm’s technology is said to aggregate natural language processing (NLP) and machine learning with human expert curation.

The collaboration will combine the biomedical knowledge with e-Therapeutics’ NDD technology to study novel disease mechanisms.

e-Therapeutics head of discovery informatics Jonny Wray said: “I’m excited we’re entering into partnership with these two companies. We already utilize machine learning heavily in our discovery platform to augment empirical biological and chemical data.

“These partnerships will enhance and extend our internal capabilities via collaborations with companies at the cutting edge of AI research and application.”

Intellegens founder Gareth Conduit said: “We believe our novel deep learning technology, specifically suited to sparse data problems, will significantly improve the data and enable more opportunities to be investigated within e-Therapeutics’ network-driven drug discovery approach.”

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply